Activist investor Carl Icahn is a busy man, who is not only attempting to push
software company BEA Systems Inc. to sell, but also is pushing for a sale at
Cambridge, Mass., biotechnology company Biogen Idec Inc.
Continue reading below
Monday's
Wall
Street Journal features an update on Icahn's activities at Biogen Idec.
Despite skepticism amongst Wall Street analysts about Biogen Idec's pipeline,
Icahn is upbeat about its future drugs saying it is an ideal takeover
candidate for a Big Pharma.
Meanwhile, Icahn is threatening to sue BEA, which responded Monday morning by
sending its biggest shareholder a letter saying it is still looking at ways to
maximize shareholder value, including a possible sale. The software company
allowed a $17 a share offer from Oracle Corp. to expire on Sunday. —
Matthew Wurtzel
See BEA Systems story from TheDeal.com
See Biogen Idec story from Wall Street Journal (subscription may be required)
See Icahn Dealwatch